NCT05430243 is a Phase 2, PHASE3 clinical trial of Empagliflozin 10 MG in Ascites Hepatic, sponsored by Alexandria University.

Who is sponsoring NCT05430243?

NCT05430243 is sponsored by Alexandria University.

What drugs are being tested in NCT05430243?

Interventions in NCT05430243: Empagliflozin 10 MG, Diuretics.

What condition does NCT05430243 study?

NCT05430243 studies Ascites Hepatic.

Is NCT05430243 still recruiting?

NCT05430243 is currently completed. Last updated 29 November 2022.

Last reviewed 2022-11-29 · How we verify

NCT05430243

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Empagliflozin as a Novel Therapy in Refractory Ascites

Completed Phase 2, PHASE3 Last updated 29 November 2022

What this trial tests

Phase 2, PHASE3 trial testing Empagliflozin 10 MG in Ascites Hepatic in 42 participants. Completed in 12 November 2022.

Timeline

21 April 2022

Primary endpoint
12 November 2022

12 November 2022

Quick facts

Lead sponsor	Alexandria University
Phase	Phase 2, PHASE3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	42
Start date	21 April 2022
Primary completion	12 November 2022
Estimated completion	12 November 2022
Sites	1 location across Egypt

Drugs / interventions tested

Empagliflozin 10 MG — full drug profile →
Diuretics — full drug profile →

Conditions studied

Ascites Hepatic — all drugs for Ascites Hepatic →

Sponsor

Alexandria University

Who can join

18 and older, any sex, with Ascites Hepatic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the present study is to investigate the safety, efficacy and cost-effectiveness of empagliflozin, a sodium glucose transporter 2 inhibitor, as an add on therapy to the standard care for refractory ascites in patients with liver cirrhosis

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacological Interventions for Cirrhotic Ascites: From Challenges to Emerging Therapeutic Horizons.
Gao Y, Liu X, Gao Y, Duan M, et al · · 2024 · cited 6× · PMID 39205495 · DOI 10.5009/gnl240038

Verify or expand the search:

Other trials of Empagliflozin 10 MG

Trials testing the same drug.

NCT03867487 — SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease · Phase 2 · not yet recruiting
NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
NCT06706791 — Effect of Empagliflozin on Quality of Life in Chronic Heart Failure Patients With Diabetes Mellitus Type II · Phase 4 · recruiting
NCT06473844 — Efficacy of SGLT2 Inhibitors in Adults With Sepsis · NA · recruiting
NCT06030843 — The Treatment Effects of Empagliflozin on Renal Outcomes in Cardiorenal Syndrome Type 1 · Phase 2, PHASE3 · recruiting

Other recruiting trials for Ascites Hepatic

Currently open trials in the same condition.

NCT06576934 — Early TIPS in Patients With Liver Cirrhosis and Ascites · NA · recruiting
NCT06669806 — Effectiveness and Safety of TIPS Stent Graft in the Treatment of Cirrhosis and Complications of Portal Hypertension · NA · recruiting
NCT07349654 — Underdilated-stent Technique Improves Post-TIPS Encephalopathy · NA · recruiting
NCT06224023 — Predictive Values of Presepsin Levels in ASciteS in Patients With Chronic Liver Failure · recruiting
NCT05999773 — SGLT-2 Inhibitors in the Treatment of Ascites · recruiting

Other Alexandria University trials

Trials by the same sponsor.

NCT07517861 — Integrated Mental Health Nursing Program: Effects on Stigma, Cognitive Flexibility, and Clinical Readiness · NA · recruiting
NCT07476482 — The Impact of a Shared Decision-Making Intervention on Intraoperative Patient Experience During Elective Cesarean Delive · NA · enrolling by invitation
NCT07476209 — Sialendoscopy Versus Photobiomodulation in Prevention of Radiation Induced Xerostomia · NA · recruiting
NCT07503626 — Optimization of Orthodontic Bracket Placement by Using Two Different Protocols of Digitally Aided Bonding · NA · recruiting
NCT07522944 — AI-Guided Relaxation for Hemodialysis Anxiety · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05430243 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Alexandria University
Last refreshed: 29 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05430243.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing